Allergan PLC agreed to sell 18 products and relinquish rights to three others to get Federal Trade Commission clearance to acquire Actavis, making it the second largest divestiture in the history of generic mergers.
The breadth of the agreement does not reflect a tougher posture by FTC, however. Seth Silber, a former advisor to FTC Chairman Jon Leibowitz, said divestiture is driven by the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?